GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » Effect of Exchange Rate Changes

Ionis Pharmaceuticals (Ionis Pharmaceuticals) Effect of Exchange Rate Changes

: $0.4 Mil (TTM As of Dec. 2023)
View and export this data going back to 1991. Start your Free Trial

Ionis Pharmaceuticals's Effect of Exchange Rate Changes for the three months ended in Dec. 2023 was $0.3 Mil.

Ionis Pharmaceuticals's Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Dec. 2023 was $0.4 Mil.

Ionis Pharmaceuticals Effect of Exchange Rate Changes Historical Data

The historical data trend for Ionis Pharmaceuticals's Effect of Exchange Rate Changes can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effect of Exchange Rate Changes
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.62 -0.11 -0.42 0.35

Ionis Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effect of Exchange Rate Changes Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.10 0.07 -0.15 0.33

Ionis Pharmaceuticals Effect of Exchange Rate Changes Calculation

Effect of Exchange Rate Changes represents the effect of exchange rate changes on cash balances held in foreign currencies.

Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Effect of Exchange Rate Changes Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Effect of Exchange Rate Changes provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » Effect of Exchange Rate Changes
Comparable Companies
BPMC BBIO APLS MDGL CRSP EXEL CYTK RVMD PCVX HALO OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
IONS:Mexico ISI:Germany ISI:Germany
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Website
https://www.ionispharma.com
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Executives
Brian Birchler officer: EVP, Corp and Development Ops C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Patrick R. O'neil officer: SVP, Legal and General Counsel C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Onaiza Cadoret-manier officer: Chief Corp Dev and Cml Officer 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eugene Schneider officer: EVP, Chf Clinical Develop Offc C/O IONIS PHARMACEUTICALS, 2855 GAZELLE CT, CARLSBAD CA 92010
Joseph Baroldi officer: Chief Business Officer C/O IONIS PHARMACEUTICALS, INC., C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eric Swayze officer: SVP, Research 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Brett P Monia director, officer: Senior Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Richard S Geary officer: Senior Vice President 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Elizabeth L Hougen officer: SVP, Finance and CFO 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
C Frank Bennett officer: Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
B Lynne Parshall director, officer: Executive Vice President, CFO 2855 GAZELLE COURT, CARLSBAD CA 92010
Joseph Iii Klein director C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Spencer R Berthelsen director 2855 GAZELLE COURT, CARLSBAD CA 92010
Frederick T Muto director 2855 GAZELLE COURT, CARLSBAD CA 92010